MY198137A - Tlr7 Agonist Trifluoroacetate Salt and Crystalline form B Thereof, Preparation Methods And Uses - Google Patents
Tlr7 Agonist Trifluoroacetate Salt and Crystalline form B Thereof, Preparation Methods And UsesInfo
- Publication number
- MY198137A MY198137A MYPI2018702700A MYPI2018702700A MY198137A MY 198137 A MY198137 A MY 198137A MY PI2018702700 A MYPI2018702700 A MY PI2018702700A MY PI2018702700 A MYPI2018702700 A MY PI2018702700A MY 198137 A MY198137 A MY 198137A
- Authority
- MY
- Malaysia
- Prior art keywords
- trifluoroacetate salt
- crystalline form
- tlr7 agonist
- preparation methods
- tlr7
- Prior art date
Links
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 title abstract 5
- 229940124615 TLR 7 agonist Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- VMDGIQUJSYPMLF-UHFFFAOYSA-N C(CCC)OC=1N=C(C2=C(N=1)C(=CN2)CC1=CC=C(C=C1)CN1CCCC1)N Chemical compound C(CCC)OC=1N=C(C2=C(N=1)C(=CN2)CC1=CC=C(C=C1)CN1CCCC1)N VMDGIQUJSYPMLF-UHFFFAOYSA-N 0.000 abstract 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610081899.3A CN107043377A (zh) | 2016-02-05 | 2016-02-05 | 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途 |
| PCT/CN2017/072894 WO2017133687A1 (zh) | 2016-02-05 | 2017-02-04 | 一种tlr7激动剂的三氟乙酸盐、晶型b、制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY198137A true MY198137A (en) | 2023-08-07 |
Family
ID=59500539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2018702700A MY198137A (en) | 2016-02-05 | 2017-02-04 | Tlr7 Agonist Trifluoroacetate Salt and Crystalline form B Thereof, Preparation Methods And Uses |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10683296B2 (OSRAM) |
| EP (1) | EP3412674B1 (OSRAM) |
| JP (1) | JP6877450B2 (OSRAM) |
| KR (1) | KR102393281B1 (OSRAM) |
| CN (2) | CN107043377A (OSRAM) |
| AR (1) | AR107550A1 (OSRAM) |
| AU (1) | AU2017214135B2 (OSRAM) |
| CA (1) | CA3013521C (OSRAM) |
| CL (1) | CL2018002101A1 (OSRAM) |
| DK (1) | DK3412674T3 (OSRAM) |
| EA (1) | EA037048B1 (OSRAM) |
| ES (1) | ES2834304T3 (OSRAM) |
| HU (1) | HUE052210T2 (OSRAM) |
| IL (1) | IL260981B (OSRAM) |
| MX (1) | MX374300B (OSRAM) |
| MY (1) | MY198137A (OSRAM) |
| NZ (1) | NZ745023A (OSRAM) |
| PH (1) | PH12018501641B1 (OSRAM) |
| SG (1) | SG11201806688QA (OSRAM) |
| TW (1) | TWI778952B (OSRAM) |
| UA (1) | UA121276C2 (OSRAM) |
| WO (1) | WO2017133687A1 (OSRAM) |
| ZA (1) | ZA201805240B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118994191A (zh) | 2016-02-05 | 2024-11-22 | 戴纳立制药公司 | 受体相互作用蛋白激酶1的抑制剂 |
| CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| EP3816166A4 (en) * | 2018-05-25 | 2022-04-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Tlr7 agonist and pharmaceutical combination thereof for treating lung cancer |
| JP7287708B2 (ja) | 2019-02-08 | 2023-06-06 | プロジェニア インコーポレイテッド | Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途 |
| JP2023516372A (ja) | 2020-03-02 | 2023-04-19 | プロジェニア インコーポレイテッド | 病原菌外壁成分基盤の生病原体模倣ナノ粒子及びその製造方法 |
| WO2022031057A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 활성화 부위가 일시적으로 비활성화된 톨-유사 수용체 7 또는 8 작용자와 기능성 약물의 결합체 및 그 용도 |
| US20230355750A1 (en) | 2020-08-04 | 2023-11-09 | Progeneer Inc. | Kinetically acting adjuvant ensemble |
| EP4194006A4 (en) | 2020-08-04 | 2024-12-04 | Progeneer Inc. | mRNA VACCINE WITH AN ADJUVANT CAPABLE OF KINETIC CONTROL |
| AU2023206890A1 (en) | 2022-01-12 | 2024-08-22 | Denali Therapeutics Inc. | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
| CN119431359A (zh) * | 2023-07-28 | 2025-02-14 | 苏州申拓医药科技有限公司 | 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3376479B2 (ja) * | 1991-08-12 | 2003-02-10 | 武田薬品工業株式会社 | 縮合ピリミジン誘導体、その製造法および用途 |
| TW201639852A (zh) | 2008-12-09 | 2016-11-16 | 吉李德科學股份有限公司 | 用於製備可用作類鐸受體調節劑之化合物的中間體化合物 |
| US9139590B2 (en) | 2011-02-04 | 2015-09-22 | Duquesne University Of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
| EP2800569B1 (en) | 2012-01-05 | 2018-07-25 | Northeastern University | Allosteric modulators of cb1 cannabinoid receptors |
| SI2906563T1 (en) * | 2012-10-10 | 2018-06-29 | Janssen Sciences Ireland Uc | Derivatives of pyrrolo (3,2-d) pyrimidine for the treatment of viral infections and other diseases |
| RU2643371C2 (ru) * | 2012-11-20 | 2018-02-01 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Новые соединения |
| MX362341B (es) * | 2014-05-01 | 2019-01-11 | Novartis Ag | Compuestos y composiciones como agonistas del receptor tipo toll 7. |
| AU2015253225B2 (en) * | 2014-05-01 | 2017-04-06 | Novartis Ag | Compounds and compositions as Toll-Like Receptor 7 agonists |
| CN105367576A (zh) * | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| SI3190113T1 (sl) * | 2014-08-15 | 2021-09-30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pirolopirimidinske spojine, ki se uporabljajo kot agonist TLR7 |
| CN105732635A (zh) * | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
-
2016
- 2016-02-05 CN CN201610081899.3A patent/CN107043377A/zh active Pending
-
2017
- 2017-02-03 TW TW106103697A patent/TWI778952B/zh active
- 2017-02-04 DK DK17747007.7T patent/DK3412674T3/da active
- 2017-02-04 MY MYPI2018702700A patent/MY198137A/en unknown
- 2017-02-04 CN CN201780009751.1A patent/CN108602833B/zh active Active
- 2017-02-04 WO PCT/CN2017/072894 patent/WO2017133687A1/zh not_active Ceased
- 2017-02-04 HU HUE17747007A patent/HUE052210T2/hu unknown
- 2017-02-04 MX MX2018009503A patent/MX374300B/es active IP Right Grant
- 2017-02-04 EA EA201891772A patent/EA037048B1/ru not_active IP Right Cessation
- 2017-02-04 SG SG11201806688QA patent/SG11201806688QA/en unknown
- 2017-02-04 NZ NZ745023A patent/NZ745023A/en unknown
- 2017-02-04 CA CA3013521A patent/CA3013521C/en active Active
- 2017-02-04 ES ES17747007T patent/ES2834304T3/es active Active
- 2017-02-04 KR KR1020187024629A patent/KR102393281B1/ko active Active
- 2017-02-04 AU AU2017214135A patent/AU2017214135B2/en active Active
- 2017-02-04 UA UAA201809128A patent/UA121276C2/uk unknown
- 2017-02-04 JP JP2018540797A patent/JP6877450B2/ja active Active
- 2017-02-04 EP EP17747007.7A patent/EP3412674B1/en active Active
- 2017-02-04 US US16/075,303 patent/US10683296B2/en active Active
- 2017-02-06 AR ARP170100299A patent/AR107550A1/es not_active Application Discontinuation
-
2018
- 2018-08-02 PH PH12018501641A patent/PH12018501641B1/en unknown
- 2018-08-03 CL CL2018002101A patent/CL2018002101A1/es unknown
- 2018-08-03 ZA ZA2018/05240A patent/ZA201805240B/en unknown
- 2018-08-05 IL IL260981A patent/IL260981B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY198137A (en) | Tlr7 Agonist Trifluoroacetate Salt and Crystalline form B Thereof, Preparation Methods And Uses | |
| PH12018501643A1 (en) | Tlr7 agonist crystalline form a, preparation method and use thereof | |
| PH12019500930A1 (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| PH12017500281A1 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
| ZA201803705B (en) | 7-(thiazol-5-yl) pyrrolopyrimidine compound as tlr7 agonist | |
| NZ747259A (en) | Soluble c5ar antagonists | |
| MX363347B (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| MX386321B (es) | Proceso para preparar un agente anticancerigeno, (1((-(4-fluoro-2-metilo-2h-indol-5-iloxi)-6-metoxiquinolin-7-iloxi) metilo) ciclopropanamina, su forma cristalina y sus sales. | |
| ZA201805185B (en) | Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms | |
| MY186698A (en) | Solid forms of ceftolozane | |
| WO2015068175A3 (en) | An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof | |
| IN2015DN02616A (OSRAM) | ||
| MX385672B (es) | Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-amina sustituida. | |
| PH12018502246A1 (en) | Substituted fused pyrimidinone compounds | |
| WO2015102017A8 (en) | Processes for the preparation of lorcaserin | |
| MY197130A (en) | Tlr7 agonist crystalline form a, preparation method and use thereof | |
| UA80534U (uk) | 1-[[3-(4,7-ДИГІДРО-1-МЕТИЛ-7-ОКСО-3-ПРОПІЛ-1Н-ПІРАЗОЛО[4,3-d]ПІРИМІДИН-5-ІЛ)-4-ЕТОКСИФЕНІЛ]СУЛЬФОНІЛ]-4-МЕТИЛПІПЕРАЗИН ТА ЙОГО ФАРМАЦЕВТИЧНО ПРИЙНЯТНІ СОЛІ | |
| IN2013CH04981A (OSRAM) | ||
| UA107549C2 (uk) | ПОХІДНІ 4,7-ДИГІДРО-5-АМІНО-3-КАРБОКСАМІДО-6-ЦІАНО[1,2,3]ТРИАЗОЛО[1,5-а]ПІРИМІДИНУ І СПОСІБ ЇХ ОДЕРЖАННЯ |